罗米芬酮 | 38373-83-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 罗米芬酮
• 中文别名: 罗米酚酮
• 英文名称: 1-(2-hydroxy-phenyl)-3-morpholin-4-yl-propan-1-one
• 英文别名: 3-Morpholino-1--propanon-(1)；2-Hydroxy-β-morpholinopropiophenon；Romifenone；1-(2-hydroxyphenyl)-3-morpholin-4-ylpropan-1-one
• CAS: 38373-83-0
• 化学式: C₁₃H₁₇NO₃
• 分子量: 235.283
• InChiKey: IFCMPBPUODFUNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  罗米芬酮 在 sodium hydride 作用下， 以 二氯甲烷 为溶剂， 反应 0.83h， 生成 4-[(E)-3-imidazol-1-yl-3-[2-(2-methylpropoxy)phenyl]prop-2-enyl]morpholine
  参考文献：
  名称：

  Synthesis and antifungal activity of new 1-vinylimidazoles

  摘要：

  Carbonyl compounds I were subjected to an imidazole transfer reaction with N,N'-sulfinyldiimidazole or N,N'-carbonyldiimidazole to obtain the diimidazole II and the monoimidazole III. Various 1-vinylimidazoles IV, derived from o-hydroxyacetophenones by imidazole transfer reaction, were alkylated to furnish the title compounds V. The structure-activity relationships of these 1-vinylimidazole compounds V are described.

  DOI：

  10.1021/jm00391a014
• 作为产物：
  描述：

  吗啉 、 聚合甲醛 、 2'-羟基苯乙酮 在 盐酸 作用下， 生成 罗米芬酮
  参考文献：
  名称：

  The Mannich Reaction of 1-(2-Hydroxyphenyl)-1-ethanone, -1-propanone and -1-butanone, and 1-(2-Hydroxy-5-methylphenyl)-2-phen-yl-1-ethanone

  摘要：

  在酸性条件下，标题化合物在甲醛存在下与仲胺反应，通过Ï-氨基甲基化得到相应的马尼奇碱。

  DOI：

  10.1055/s-1988-27725

文献信息

• Mechanistic studies on counter-ionic effects of camphorsulfonate-based ionic liquids on kinetics, thermodynamics and stereoselectivity of β-amino carbonyl compounds
  作者：Sabahat Sardar、Erum Jabeen、Cecilia Devi Wilfred、Ahmad Sazali Hamzah、Jean-Marc Leveque

  DOI：10.1016/j.molliq.2020.114370

  日期：2020.12

  Catalysis is important in various applications of organic chemistry and its output product control for stereoselective compounds is outrageous. Establishment of experimental facts of stereoselective compounds from catalysis and their validation using theoretical evidences is the key to understand various mechanisms of optically active compounds. A family of new ionic liquids (ILs) with various imidazolium

  催化作用在有机化学的各种应用中很重要，其对立体选择化合物的输出产物控制非常苛刻。通过催化作用建立立体选择性化合物的实验事实，并使用理论证据对其进行验证，是理解旋光化合物各种机理的关键。已经合成了具有各种咪唑鎓阳离子和樟脑磺酸根阴离子作为对环境有益的液态盐的一系列新型离子液体（IL），并将其用于催化β-氨基羰基化合物。使用IL作为均相催化剂形成产物，具有优异的产物收率和非对映选择性。根据反应动力学和产物收率，研究了抗衡离子，IL的哈米特酸度和粘度以及溶剂和温度的影响。密度泛函理论（DFT）用于研究反应机理的热力学研究。DFT计算预测，催化机理涉及IL的两个抗衡离子。此外，有证据表明，合成途径需要较低的活化能，而反途径产生热力学稳定的产物。这项研究探索了使用IL作为潜在的均相催化剂生产立体选择性物质的新途径。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents
  申请人：Ethicon, Inc.

  公开号：US11452641B2

  公开（公告）日：2022-09-27

  A surgical incision drape, comprises a flexible substantially flat areal substrate having an upper side and an opposing tissue-facing side, having a longitudinal axis and a pressure sensitive adhesive disposed on the tissue-facing side; at least one hollow microtubular compartment containing a flowable medical agent, said hollow microtubular compartment positioned to intersect the longitudinal axis and embedded into the substrate or positioned on the substrate.

  一种手术切口敷料，包括一个柔性大体平坦的基底，基底有一个上侧和一个相对的面向组织的侧，基底有一个纵轴，面向组织的侧上有一个压敏粘合剂；至少一个中空微管隔室，内装可流动的医用制剂，所述中空微管隔室的位置与纵轴相交，并嵌入基底或设置在基底上。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13